Shingles vaccine cuts dementia risk by up to 40pc, study finds - The Telegraph

Direct Source Verification: This story is aggregated from The Telegraph (telegraph.co.uk). Full reporting rights and copyright belong to the primary publisher.
Laura has led award-winning coverage on the NHS, medical science breakthroughs, and public health policy across the UK for The Telegraph. Her reporting can be found on X: @lauradonnlee

Laura has led award-winning coverage on the NHS, medical science breakthroughs, and public health policy across the UK for The Telegraph. Her reporting can be found on X: @lauradonnlee

A shingles jab could cut the risk of dementia by almost 40 per cent, research suggests.

The latest study suggests the vaccine may offer greater protection against dementia than previously thought, building on earlier research in Wales that found it reduced the risk by 20 per cent.

That research helped fuel a surge in people paying privately for shingles jabs, with bookings at Boots, the high-street chemist, more than doubling in the past year.

The findings were presented at the Clinical Trials on Alzheimer’s Disease conference in Boston by Dr Richard Haarburger, who collaborated with researchers at Stanford University and Victoria University of Wellington in New Zealand.

They found stronger effects among women, who account for about two-thirds of Alzheimer’s patients, and suggested benefits across common types of dementia.

Researchers examined what happened after New Zealand introduced publicly funded shingles vaccinations for people aged 65 to 80 in April 2018.

They calculated that the injection reduced the likelihood of a dementia diagnosis by 37.6 per cent, equivalent to approximately 25 fewer cases for every 1,000 people vaccinated.

Under the programme’s eligibility rules, some people who had just turned 81 were excluded, while those born just days later qualified.

This created a natural comparison between people of almost identical ages who were treated differently under the scheme.

People who had just turned 81 were excluded, while those whose birthdays fell just after the programme began qualified.

Vaccination uptake was just 0.2 per cent among those immediately outside the eligibility threshold, compared with 26 per cent among those just inside it.

Researchers used that difference to estimate the vaccine’s effect over the following five years.

The approach helps overcome a major difficulty with studies comparing vaccinated and unvaccinated people: those choosing vaccination may already be more health-conscious.

They might exercise more, seek medical help earlier or differ in other ways that affect their chances of developing dementia.

Comparing people born just days apart allowed researchers to isolate the vaccine’s effects while minimising the influence of other differences.

Scientists describe this as a “natural experiment”, since eligibility was determined by government policy rather than personal choice.

In the UK, shingles vaccinations are available on the NHS to people aged 70 to 79, with eligibility gradually being extended to those aged 65 and over. Adults with severely weakened immune systems can also qualify.

Those who do not qualify can pay privately for a vaccination, Boots recently reported that bookings more than doubled in the year to September 2026, following a 30 per cent increase the previous year. Superdrug reported a 41 per cent annual increase in bookings.

A two-course dose of Shingrix costs about £460 and is available privately to those aged 50 and over.

The Government has committed to extending the NHS shingles vaccination programme to people aged 60 and over from 2028, following recommendations from the Joint Committee on Vaccination and Immunisation (JCVI).

Last year, the JCVI considered whether shingles jabs could prevent dementia, but concluded that more research was needed before changing its recommendations. It said it would keep emerging findings under review.

Dr Sheona Scales, director of research at Alzheimer’s Research UK, said: “These findings add to growing evidence that shingles vaccination could play a role in reducing dementia risk.

“It is particularly interesting to see researchers using innovative study designs to explore this question, making use of vaccine rollouts to help distinguish the effects of vaccination from other factors.

“While further research is needed to establish whether vaccination can prevent or delay dementia, we look forward to seeing how this evidence develops as other studies investigating this question report their findings.

“It is encouraging to see such a diverse range of potential treatments and approaches being explored to tackle Alzheimer’s. Broadening the scope of this research will be essential if we are to make meaningful progress against the disease.”

The New Zealand research largely examined an older shingles vaccine, Zostavax, but separate studies suggest the newer Shingrix jab, now used in Britain, may offer even greater protection against dementia.

The earlier Welsh research, published in Nature last year, examined records from 282,541 adults and followed dementia diagnoses over seven years.

Both studies used birthday cut-offs to compare people of almost identical ages who had different chances of receiving vaccination.

However, the latest study was not a randomised clinical trial, and the findings cannot establish whether vaccination prevents dementia altogether or postpones diagnosis beyond the follow-up period.

Kathryn Carnazza, of the Alzheimer’s Drug Discovery Foundation, said health systems could consider offering shingles jabs at a younger age in light of the findings.

She said: “Countries where vaccination eligibility begins at an older age could consider this evidence when reviewing their policies.”

A Department of Health and Social Care spokesman said: “We are seeing some promising studies examining the link between shingles vaccination and reduced dementia risk, and we look forward to examining this latest report.

“As always, it will be for the JCVI to assess the evidence and advise government accordingly.

“In the meantime, this Government is committed to taking action to tackle dementia through improved research, care and treatment.”

Original Source
https://www.telegraph.co.uk/news/2026/11/17/shingles-vaccine-cut-dementia-risk-40pc-study-wales-zealand/
Visit The Telegraph ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health